抗血管內皮生長因子療法市場－全球產業規模、佔有率、趨勢、機會和預測，按產品、疾病、最終用戶、地區和競爭格局分類，2020-2030年預測

2024年全球抗血管內皮生長因子（VEGF）療法市場規模為143.8億美元，預計2030年將以3.65%的複合年成長率成長至178.3億美元。抗VEGF療法是一類生物製劑，旨在抑制新血管的形成，而新血管的形成是多種疾病進展的關鍵過程。這些療法主要用於治療眼科疾病，例如老年黃斑部病變和糖尿病性黃斑水腫，以及多種癌症。

主要市場促進因素

全球眼科疾病，特別是老年黃斑部病變（AMD）和糖尿病黃斑水腫（DME）的日益流行，極大地推動了抗血管內皮生長因子療法市場的發展。這些致盲性疾病是全球失明和嚴重視力障礙的主要原因，因此亟需有效且持續的藥物介入。

主要市場挑戰

全球抗血管內皮生長因子療法市場面臨多種成熟生物製劑專利即將到期的嚴峻挑戰。預計這種情況將加劇生物相似藥之間的競爭，從而直接影響原廠藥生產商的市場動態。

主要市場趨勢

全球抗血管內皮生長因子（VEGF）療法市場受到抗VEGF生物相似藥市場滲透率不斷提高的顯著影響。這一趨勢的驅動力在於提高成本效益並擴大患者獲得關鍵療法的機會，尤其是在主要原研究生物製劑專利即將到期的情況下。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球抗血管內皮生長因子療法市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（Eylea、Lucentis、Beovu）
  • 依疾病分類（黃斑水腫、糖尿病視網膜病變、視網膜靜脈阻塞、老年黃斑部病變）
  • 依最終使用者（醫院和診所、門診中心、其他）分類
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美抗血管內皮生長因子療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲抗血管內皮生長因子療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區抗血管內皮生長因子療法市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲抗血管內皮生長因子療法市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲抗血管內皮生長因子療法市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球抗血管內皮生長因子療法市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• F. Hoffmann-La Roche Ltd.
• Biogen MA Inc.
• Pfizer Inc.
• Coherus BioSciences, Inc.
• Amgen Inc.
• Viatris Inc.
• Bausch Health Companies Inc.
• Novartis AG
• Regeneron Pharmaceuticals Inc.

第16章：策略建議

第17章調查會社について,免責事項

The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, valued at USD 14.38 Billion in 2024, is projected to experience a CAGR of 3.65% to reach USD 17.83 Billion by 2030. Anti-vascular endothelial growth factor (VEGF) therapeutics are a class of biological drugs designed to inhibit the formation of new blood vessels, a process crucial in the progression of various diseases. These therapies are predominantly utilized in the treatment of ophthalmic conditions, such as age-related macular degeneration and diabetic macular edema, as well as several types of cancer.

Key Market Drivers

The escalating global prevalence of ophthalmic diseases, particularly age-related macular degeneration (AMD) and diabetic macular edema (DME), serves as a substantial impetus for the anti-vascular endothelial growth factor therapeutics market. These debilitating conditions, which are leading causes of blindness and severe vision impairment worldwide, necessitate effective and sustained pharmacological intervention. Enhanced diagnostic capabilities and improved patient access to ophthalmological care contribute to a larger identified patient pool requiring treatment.

Key Market Challenges

The global anti-vascular endothelial growth factor therapeutics market faces a significant challenge from the impending patent expirations of several established biological drugs. This scenario is expected to intensify biosimilar competition, which directly influences the market dynamics for originator manufacturers. As biosimilar versions become available, they enter the market at considerably lower prices to gain market share. This increased competition drives down the average selling prices across the entire product class.

Key Market Trends

The Global Anti-Vascular Endothelial Growth Factor (VEGF) Therapeutics Market is significantly shaped by the expanding market penetration of anti-VEGF biosimilars. This trend is driven by the imperative to enhance cost-effectiveness and broaden patient access to critical therapies, particularly as key originator biologics face patent expirations. Biosimilars introduce robust price competition, thereby fostering greater affordability and increasing the overall volume of anti-VEGF treatments dispensed.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Biogen MA Inc.
• Pfizer Inc.
• Coherus BioSciences, Inc.
• Amgen Inc.
• Viatris Inc.
• Bausch Health Companies Inc.
• Novartis AG
• Regeneron Pharmaceuticals Inc.

Report Scope:

In this report, the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Product:

• Eylea
• Lucentis
• Beovu

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Disease:

• Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Age-related Macular Degeneration

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By End Users:

• Hospitals & Clinics
• Ambulatory Care centers
• Others

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market.

Available Customizations:

Global Anti-Vascular Endothelial Growth Factor Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Eylea, Lucentis, Beovu)
  • 5.2.2. By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration)
  • 5.2.3. By End Users (Hospitals & Clinics, Ambulatory Care centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Disease
  • 6.2.3. By End Users
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Disease
      • 6.3.1.2.3. By End Users
  • 6.3.2. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Disease
      • 6.3.2.2.3. By End Users
  • 6.3.3. Mexico Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Disease
      • 6.3.3.2.3. By End Users

7. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Disease
  • 7.2.3. By End Users
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Disease
      • 7.3.1.2.3. By End Users
  • 7.3.2. France Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Disease
      • 7.3.2.2.3. By End Users
  • 7.3.3. United Kingdom Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Disease
      • 7.3.3.2.3. By End Users
  • 7.3.4. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Disease
      • 7.3.4.2.3. By End Users
  • 7.3.5. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Disease
      • 7.3.5.2.3. By End Users

8. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Disease
  • 8.2.3. By End Users
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Disease
      • 8.3.1.2.3. By End Users
  • 8.3.2. India Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Disease
      • 8.3.2.2.3. By End Users
  • 8.3.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Disease
      • 8.3.3.2.3. By End Users
  • 8.3.4. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Disease
      • 8.3.4.2.3. By End Users
  • 8.3.5. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Disease
      • 8.3.5.2.3. By End Users

9. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Disease
  • 9.2.3. By End Users
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Disease
      • 9.3.1.2.3. By End Users
  • 9.3.2. UAE Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Disease
      • 9.3.2.2.3. By End Users
  • 9.3.3. South Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Disease
      • 9.3.3.2.3. By End Users

10. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Disease
  • 10.2.3. By End Users
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Disease
      • 10.3.1.2.3. By End Users
  • 10.3.2. Colombia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Disease
      • 10.3.2.2.3. By End Users
  • 10.3.3. Argentina Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Disease
      • 10.3.3.2.3. By End Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biogen MA Inc.
• 15.3. Pfizer Inc.
• 15.4. Coherus BioSciences, Inc.
• 15.5. Amgen Inc.
• 15.6. Viatris Inc.
• 15.7. Bausch Health Companies Inc.
• 15.8. Novartis AG
• 15.9. Regeneron Pharmaceuticals Inc.

16. Strategic Recommendations

17. About Us & Disclaimer